NEW YORK, Nov. 18, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Dynavax Technologies Corporation (NASDAQ:DVAX) between January 7, 2016 and November 11, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information go to:
http://www.zlk.com/pslra/dynavax-technologies
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period Dynavax made false and/or misleading statements and/or failed to disclose that: (i) the phase 3 HBV-23 trial for the Company’s lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration’s concerns and issues, as pointed out in a 2013 Complete Response Letter; (ii) Dynavax failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; (iii) Dynavax’s resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and (iv) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Dynavax’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Dynavax you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Anta Sports Expands Global Footprint With Strategic Puma Stake
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



